Compare Enveric Biosciences Inc (ENVB) vs iShares MSCI Canada (TSX) (EWC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MSCI Canada (TSX) — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares MSCI Canada (TSX) trades at $58.3 (market cap $7.14B). The key difference: iShares MSCI Canada (TSX) is far larger — about 1067.3× Enveric Biosciences Inc's market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares MSCI Canada (TSX) for 57 Days on average.
| ENVB | EWC | |
|---|---|---|
Market Cap | $6.69M | $7.14B |
Volume | 41,141 | 2,496,812 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $62.64 |
52-Week Low | $1.27 | $49.72 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
EWC is trading at $57.94, down 2.1% with a bearish technical signal as moving averages indicate selling pressure while oscillators remain neutral. The stock shows oversold conditions with RSI readings below 30, suggesting potential for near-term bounce. Recent news highlights Canada's trade tensions with the US and potential EU associate membership discussions creating market uncertainty.
The outlook remains cautious given trade policy risks and technical weakness, though oversold conditions may provide short-term opportunities. Key risks include US-Canada trade disputes and economic sensitivity to external shocks, while potential EU alignment could offer diversification benefits if negotiations progress favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →
